

**Louisiana Medicaid
Hepatitis C Direct-Acting Antiviral (DAA) Agents**

To request authorization for **non-preferred** DAA agents, the prescriber must submit the following documents which must be completed, dated and signed by the prescriber - signature stamps and proxy signatures are not acceptable:

- *Louisiana Uniform Prescription Drug Prior Authorization Form; AND*
- *Direct-Acting Antiviral (DAA) Agents Used to Treat Chronic Hepatitis C Virus (HCV) Medication Therapy Worksheet for Louisiana Medicaid Recipients; AND*
- *Direct-Acting Antiviral (DAA) Agents Used to Treat Chronic Hepatitis C Virus (HCV) Treatment Agreement for Louisiana Medicaid Recipients. Each item on the Hepatitis C Therapy Treatment Agreement must be initialed by the recipient, and the agreement must be dated and signed by the recipient.*

Additional Point-of-Sale edits may apply.

The authorized generic (AG) of Epclusa® is preferred and does not require authorization. However, point-of-sale (POS) edits may apply (see POS document).

NOTE: Some medications in this therapeutic class may have **Black Box Warnings** and/or may be subject to **Risk Evaluation and Mitigation Strategy (REMS)** under FDA safety regulations; refer to individual prescribing information for details.

ALL of the following are required when requesting non-preferred agents:

- The recipient has a diagnosis of chronic hepatitis C (B18.2) and appropriate genotype for agent requested (see Table 1); **AND**
- The recipient's age (~~and~~ or weight, as applicable — see Table 2) is appropriate for the requested medication (see POS document); **AND**
- There is no preferred alternative that is the exact same chemical entity, formulation, strength, etc. (e.g., for requested non-preferred generic Epclusa® and brand Epclusa®, the preferred authorized generic for Epclusa® is the exact same chemical entity, formulation, strength, etc.); **AND**
- Previous use of a preferred product - **ONE** of the following is required:
 - The recipient has had a *treatment failure* with at least one preferred product; **OR**
 - The recipient has had an *intolerable side effect* to at least one preferred product; **OR**
 - The recipient has *documented contraindication(s)* to the preferred products that are appropriate to use for the condition being treated; **OR**
 - There is *no preferred product that is appropriate* to use for the condition being treated; **OR**
 - The prescriber states that the recipient is currently using the requested medication, and the request is to complete the patient-specific course of treatment recommended in the prescribing information (see POS document); **AND**
- By submitting the authorization request, the prescriber attests to the following:
 - The prescribing information for the requested medication (and all other medications used in a combination hepatitis C virus treatment regimen) has been thoroughly reviewed, including any Black Box Warning, Risk Evaluation and Mitigation

Strategy (REMS), contraindications, minimum age requirements, recommended dosing, and prior treatment requirements; **AND**

- All laboratory testing and clinical monitoring recommended in the prescribing information have been completed as of the date of the request and will be repeated as recommended (including renal function, hepatic state and monitoring for reactivation of hepatitis B); **AND**
- The recipient has no concomitant drug therapies or disease states that limit the use of the requested DAA agent.

Duration of authorization approval: Up to maximum duration of therapy depending upon patient-specific factors (see POS document).

Table 1. Genotype Indications	
Treatment	Indicated for Genotype(s)
Daclatasvir (Daklinza®)	1, 3
Elbasvir/Grazoprevir (Zepatier®)	1, 4
Glecaprevir/Pibrentasvir (Mavyret®)	1, 2, 3, 4, 5, 6
Ledipasvir/Sofosbuvir (Harvoni®; Authorized Generic)	1, 4, 5, 6
Ombitasvir/Paritaprevir/Ritonavir with Dasabuvir (Viekira PAK®)	1
Sofosbuvir (Sovaldi®)	1, 2, 3, 4
Sofosbuvir/Velpatasvir (Epclusa®; Authorized Generic)	1, 2, 3, 4, 5, 6
Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi®)	1, 2, 3, 4, 5, 6

Table 2. Minimum Indicated Age	
Treatment	Minimum Age
Daclatasvir (Daklinza®)	<u>> 18 years</u>
Elbasvir/Grazoprevir (Zepatier®)	<u>> 18 years</u>
Glecaprevir/Pibrentasvir (Mavyret®)	<u>> 12 years*</u>
Ledipasvir/Sofosbuvir (Harvoni®; Authorized Generic)	<u>> 3 years</u>
Ombitasvir/Paritaprevir/Ritonavir with Dasabuvir (Viekira PAK®)	<u>> 18 years</u>
Sofosbuvir (Sovaldi®)	<u>> 3 years**</u>
Sofosbuvir/Velpatasvir (Epclusa®)	<u>> 18 years</u>
Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi®)	<u>> 18 years</u>

* Recipients younger than 12 years of age must weigh at least 45kg.

** Recipients 3-17 years of age must have genotype 2 or 3 without cirrhosis or with compensated cirrhosis.

References

American Association for the Study of Liver Diseases (AASLD) and the Infectious Disease Society of American (IDSA). (2015). Recommendations for testing, managing, and treating hepatitis C. <http://www.hcvguidelines.org/full-report-view>

Daklinza (daclatasvir) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; October 2019. https://packageinserts.bms.com/pi/pi_daklinza.pdf

Formatted: Font: Not Bold, Italic

Formatted: Font: Not Bold, Italic

Formatted: Font: Italic

Formatted: Font: Not Bold, Italic

Formatted: Font: Italic

Formatted: Font: Italic

Formatted: Font: Not Bold, Italic

Epclusa (sofosbuvir/velpatasvir) [package insert]. Foster City, CA: Gilead Sciences, Inc.; November 2019. https://www.gilead.com/~media/Files/pdfs/medicines/liver-disease/epclusa/epclusa_pi.pdf

Ghany MC, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. *Hepatology*. 2009;49(4):1335-1374.

Harvoni (ledipasvir/sofosbuvir) [package insert]. Foster City, CA: Gilead Sciences, Inc.; November 2019. https://www.gilead.com/~media/files/pdfs/medicines/liver-disease/harvoni/harvoni_pi.pdf

Ledipasvir/Sofosbuvir (authorized generic of harvoni) [package insert]. Foster City, CA: Asegu Therapeutics LLC (An affiliate of Gilead Sciences, Inc); November 2019. https://www.asegua.com/~media/Files/pdfs/medicines/liver-disease/asegua/asegua_ldv_sof_pi.pdf

Mavyret (glecaprevir/pibrentasvir) [package insert]. North Chicago, IL: AbbVie Inc.; September 2019. https://www.rxabbvie.com/pdf/mavyret_pi.pdf

Oregon Health & Sciences University Center for Evidence-based Policy, Medicaid Evidence Based Decisions Project (MED). (2014). Sofosbuvir for the treatment of hepatitis C and evaluation of the 2014 American Association for the Study of Liver Diseases treatment guidelines. http://www.ohsu.edu/xd/research/centers-institutes/evidence-based-policycenter/med/upload/Sofosbuvir_for_HepatitisC_FINALDRAFT_6_12_2014.pdf

Sofosbuvir/Velpatasvir (authorized generic of epclusa) [package insert]. Foster City, CA: Asegu Therapeutics LLC (An affiliate of Gilead Sciences, Inc); November 2019. https://www.asegua.com/~media/Files/pdfs/medicines/liver-disease/asegua/asegua_sof_vel_pi.pdf

Sovaldi (sofosbuvir) [package insert]. Foster City, CA: Gilead Sciences, Inc.; September 2019. https://www.gilead.com/~media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi_pi.pdf

U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). (2003). Guidance for Industry: Pharmacokinetics in Recipients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling. <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072123.pdf>

U.S. Food and Drug Administration. FDA approves two hepatitis C drugs for pediatric recipients. (2017). <https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm551407.htm>

Veterans Affairs National Hepatitis C Resource Center Program and the Office of Public Health. (2015). Chronic Hepatitis C Virus (HCV) Infection: Treatment Considerations from the

Department of Veterans Affairs National Hepatitis C Resource Center Program and the Office of Public Health. <http://www.hepatitis.va.gov/pdf/treatment-considerations-2015-07.pdf>

Viekira PAK (ombitasvir/paritaprevir/ritonavir with dasabuvir) [package insert]. North Chicago, IL: AbbVie Inc.; July 2018. https://www.rxabbvie.com/pdf/viekirapak_pi.pdf

Vosevi (sofosbuvir/velpatasvir/voxilaprevir) [package insert]. Foster City, CA: Gilead Sciences, Inc.; November 2019. https://www.gilead.com/-/media/files/pdfs/medicines/liver-disease/vosevi/vosevi_pi.pdf

Zepatier (elbasvir/grazoprevir) [package insert]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp.; June 2018. https://www.merck.com/product/usa/pi_circulars/z/zepatier/zepatier_pi.pdf

Revision	Date
Single PDL Implementation	May 2019
Removed Fee-for-Service from title, added wording that AG Epclusa® does not require prior-authorization, moved genotype/age/quantity limit for each agent to tables, modified duration of therapy for Mavyret® per prescribing information, removed other drug-specific criteria wording, added Vosevi genotype/age/duration/quantity limit to tables.	July 2019
Moved all point-of-sale information <u>except minimum age</u> to the POS document	May 2020